Teva Pharmaceutical Industries launched its Adasuve inhaled powder for the treatment of agitation associated with schizophrenia and bipolar I disorder in the U.S. The drug is the first of its kind with this delivery system, which uses Alexza Pharmaceuticals' Staccato device for absorption in the lungs.
Alexza Pharmaceuticals' Adasuve, the company's inhaled form of the antipsychotic loxapine, has finally been approved in the U.S. for rapid treatment of the agitation seen in schizophrenia and bipolar disorder, and could be available by the third quarter of 2013.
Even with a beefed up international commercial partnership, a public offering, restructuring and layoffs, Alexza Pharmaceuticals ($ALXA) has disclosed that its cash could run out by year-end.
The FDA slammed Alexza Pharmaceuticals ($ALXA) with another setback this week in its drive to bring the antipsychotic drug Adasuve to market. Regulators are extending by three months their review of
Alexza Pharmaceuticals may be literally going for broke as it pursues approval of its inhaled fast-acting antipsychotic drug Adasuve. The company ($ALXA) announced that it will pursue significant,